Glaxo SmithKline OTC Switch Potential Seen As Merger Catalyst
This article was originally published in The Tan Sheet
Executive Summary
The Rx influenza treatment Relenza tops the list of potential OTC switch candidates in the Glaxo SmithKline portfolio, according to merger details announced the week of Jan. 17.
You may also be interested in...
GlaxoSmithKline Merger Completion Delayed To Year-End
The planned merger of SmithKline Beecham and Glaxo Wellcome will be delayed, likely until the end of the year, due to continued Federal Trade Commission inquiries.
OTC Antiviral Agents For Herpes Cold Sores Disfavored By FDA
The future of potential OTC antiviral treatments for herpes labialis, including Avanir Pharmaceuticals' docosanol 10% cream, is questionable in light of FDA's announcement that it disfavors use of such antiviral drugs in a nonprescription setting.
Warner-Lambert/Pfizer Consumer Healthcare Sales Top $3.5 Bil.
The combination of Warner-Lambert and Pfizer will create a firm with consumer healthcare sales of over $3.5 bil., based on 1999 results, with W-L contributing roughly $3 bil. of the total.